Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,848 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05189054Recruiting
Radiation retreatment for very central chest tumors
This trial tests a focused form of radiation (SBRT) to treat tumors in the very center of the chest that have already been treated with radiation before. It aims to check safety and whether the tumor can be controlled without causing unacceptable side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT06226857RecruitingPhase 3
Anti-EGFR for left-sided, RAS wild-type metastatic colorectal cancer
This trial tests whether anti-EGFR therapy works better for people with left-sided colorectal cancer that has spread, whose tumors do not have certain gene mutations (RAS wild-type). It is for those who have not yet had treatment for metastatic disease.
MoscowAges 18–99 - NCT05760378RecruitingPhase 3
Famitinib plus immunotherapy for advanced triple-negative breast cancer
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06321939Recruiting
Tracking EBV DNA in Blood for Nasopharyngeal Cancer
This trial studies whether tracking levels of Epstein-Barr virus DNA in your blood can help guide treatment for non-metastatic nasopharyngeal cancer. You would get standard radiation and maybe chemotherapy, with extra blood tests to see how the virus levels change.
Changsha, HunanAges 18 years+ - NCT06341907RecruitingPhase 2/Phase 3
Vaccine and blood test to prevent ovarian cancer return
This trial tests a personalized vaccine for people with epithelial ovarian cancer who still have a small amount of cancer DNA in their blood after surgery. The goal is to see if the vaccine can help stop the cancer from coming back.
Wenzhou, ZhejiangAges 18–70 - NCT06280508RecruitingPhase 2
Perioperative chemo plus immunotherapy for bile duct cancer
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
Guangzhou, China/GuangdongAges 18 years+ - NCT03659448RecruitingPhase 3
Test drug that helps map colon and rectal cancer during surgery
This Phase 3 study tests SGM-101, a drug used during surgery to help doctors better outline primary, recurrent, and spread (metastatic) colorectal cancer. It may improve how completely tumors are identified and removed during an operation.
Duarte, CaliforniaAges 18 years+ - NCT06441110RecruitingPhase 3
BCG instillation for medium- to high-risk bladder cancer
This trial tests whether a specific schedule of BCG (a weakened germ that boosts the immune system) placed directly into the bladder is safe and effective for medium- to high-risk bladder cancer that hasn't grown into the muscle. It aims to see if adjusting the standard BCG course can work better for people with a PD-L1-positive tumor.
Fuzhou, FujianAges 18–75 - NCT07840092Recruiting
Blood and tissue markers for liver cancer treatment response
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
TianjinAges 18 years+ - NCT07839767Recruiting
Personalized treatment to prevent liver cancer recurrence
This study uses a 3D-printed model of your liver tumor to help doctors choose treatment that may prevent the cancer from coming back after surgery. The model predicts how your tumor might respond, so you get the most effective therapy.
Hong KongAges 18 years+ - NCT06359275RecruitingPhase 2
Combination therapy for locally advanced or recurrent pancreatic cancer
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
ShanhaiAges 18–75 - NCT06086197RecruitingPhase 2
A drug combo for early relapsed or refractory DLBCL
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
Hangzhou, ZhejiangAges 18 years+ - NCT07807163RecruitingPhase 2
Study of ficerafusp alfa with pembrolizumab for head and neck cancer
This study tests a new drug called ficerafusp alfa combined with pembrolizumab (an immunotherapy) in people with head and neck cancer that has returned or spread. The drug targets a protein that may help the immune system fight the cancer. The study is comparing two different schedules of giving the drug to see which is better.
Fort Myers, FloridaAges 18 years+ - NCT07795034RecruitingPhase 2
Boron neutron therapy for recurrent head and neck cancer
This trial tests a new type of radiation therapy (boron neutron capture therapy) combined with two drugs for people whose head or neck cancer has returned and standard treatments have failed. It aims to see if this combination can shrink tumors and is safe.
Xiamen, FujianAges 18–75 - NCT06551207Recruiting
New drug combo with radiation for advanced MSS colon cancer
This trial tests a new combination—an immunotherapy drug (cadonilimab) plus a targeted anti-angiogenesis pill (fruquintinib) and focused radiation (SBRT)—for people with MSS colorectal cancer that has progressed after at least two prior treatments. The goal is to see if this triple approach can help shrink or control the cancer better than standard options.
Wuhan, HubeiAges 18–75 - NCT06561178Recruiting
Blood Test to Monitor Esophageal Cancer After Surgery
This trial looks at whether a personalized blood test can detect cancer returning after surgery for esophageal cancer. It tests people who had chemoradiotherapy before surgery and still had some cancer remaining in the removed tissue. The goal is to use the blood test to catch any remaining or returning cancer early.
Guangzhou, GuangdongAges Any age - NCT06590506Recruiting
Wearable health tracking for advanced solid tumor treatment
This trial studies how using a wearable device and smartphone app can help monitor your health during your first cancer treatment for advanced solid tumors. You will receive a known therapy (not a placebo), and the research team will collect real-world data to improve care.
A Coruña, A Coruña/ GaliciaAges 18 years+ - NCT06587425RecruitingPhase 2
Combination therapy for CLDN18.2-positive advanced stomach cancer
This study tests a combination of three drugs (LM-302, Candonilimab, and Capecitabine) as the first treatment for advanced stomach cancer that has a specific protein (Claudin 18.2). It aims to see if the combination shrinks tumors and is safe.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT02292641Recruiting
MRI study for repeat pelvic colorectal cancer
This study uses a special MRI to help understand and stage colorectal cancer that has come back in the pelvis. The goal is to improve how doctors make treatment decisions after previous surgery.
OsloAges 16 years+ - NCT07705243RecruitingPhase 3
Maintenance therapy for advanced nasopharyngeal cancer
This trial tests a combination of two drugs (becotatug vedotin and an anti-PD1 immunotherapy) as maintenance treatment after initial chemotherapy for advanced nasopharyngeal cancer that has spread or returned. It's for people whose disease has not progressed after standard first-line treatment.
Guangzhou, GuangdongAges 18–75 - NCT06390774RecruitingPhase 1
Study of SSGJ-705 for advanced cancers
This phase 1 trial tests a new targeted drug (SSGJ-705) for people with advanced solid tumors or lymphomas. Doctors will check safety and find the best dose, and there may be a chance the drug helps shrink or control the cancer.
Jinan, ShandongAges 18–75 - NCT07690787RecruitingPhase 2
Study of JS207 for nasopharyngeal cancer
This trial tests a new drug, JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow. It's for people with nasopharyngeal cancer that has not spread too much, and who have not had certain prior treatments.
Hong KongAges 18 years+ - NCT07673367RecruitingPhase 2
Nemtabrutinib with CAR T for relapsed mantle cell lymphoma
This trial tests adding a targeted pill (nemtabrutinib) to standard CAR T-cell therapy for people with mantle cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination works better than CAR T alone.
Nashville, TennesseeAges 18 years+ - NCT07668154RecruitingPhase 2
Testing SKB571 for advanced head and neck cancer
This study tests a new drug called SKB571 for people whose head and neck cancer (a type called squamous cell carcinoma) has come back or spread and cannot be surgically removed. The goal is to see if the drug is safe and effective.
ChengduAges 18–75
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,848 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.